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COMMENTARY
MEDICINE AND LAW
Biosafety Concerns Involving Genetically
Modified Mosquitoes to Combat Malaria
and Dengue in Developing Countries
Graciela R. Ostera, PhD
Lawrence O. Gostin, JD
THROUGHOUT HISTORY, MOSQUITOES HAVE BEEN DIS-ease vectors in human settlements in every region.Today, mosquito-transmitted diseases are presentmainly in the equatorial belt, posing major risks to
half the world’s population and causing disease in 700 mil-
lion individuals annually. Malaria and dengue are the most
prevalent mosquito-borne infections, but West Nile virus
in the Americas and chikungunya and Japanese encephali-
tis in Asia and Oceania are rapidly emerging.1 Typical areas
and conditions for transmission are increasing, attribut-
able to global climatic changes as well as wider dissemina-
tion of virulent viral strains.1,2
Malaria causesmore than 250million infections andnearly
1 million deaths annually,3 with 90% of fatal cases occur-
ring in infants and children, typically in sub-Saharan Africa.
The malaria parasite, a Plasmodium protozoan, is transmit-
ted through the bite of an Anopheles mosquito.3 Dengue in-
fection is traditionally present in hyperendemic regions in
Southeast Asia, as well as in Africa and Central and South
America. Dengue causes 50million to 100million cases an-
nually, of which 500 000 progress to the lethal form den-
gue hemorrhagic fever or dengue shock syndrome.4 Den-
gue is caused by a family of viruses transmitted mainly by
the Aedes aegypti mosquito and shares a common ancestry
with the causative agent of yellow fever.1,4
Scientific Innovations in Mosquito Control
The global response to mosquito-borne infections still re-
lies on low-technology interventions, such as swamp drain-
age to reduce larval habitats, indoor spraying with residual
insecticides, and the use of insecticide-impregnated nets. Tra-
ditional interventions, however, pose challenges, such as the
increase of insecticide-resistant mosquitoes, environmen-
tal concerns with insecticides, and the difficulty in distrib-
uting and reliably using bed nets.
Prompted by global health advocates, scientists are consid-
ering innovative solutions such as the elimination of global
mosquito populations.5 However, elimination would be ex-
traordinarily complex, with some 3500 mosquito species in
virtually all geographical regions. Even if itwerepossible,mos-
quito elimination could be undesirable because only a small
proportion of all mosquitoes are human disease vectors, and
wide extermination could have serious ecosystem effects.
Given the impracticality of mosquito elimination, scien-
tists are making significant advances in the generation of
genetically modified mosquitoes that are unable to trans-
mit disease. Proponents speculate that genetically modi-
fied mosquitoes would cause minimal ecological disrup-
tion because targeted mosquito species would still occupy
their ecological niche, simultaneously preventing the inva-
sive displacement by other species.
Elucidation of the full-length genomic sequences ofAnoph-
eles gambiae (the primary vector for malaria in Africa) in
2002 and Aedes aegypti in 2007 provided the basic tools to
modify the vector capacity of these organisms. Scientists have
recently confirmed the geneticmodification ofAnopheles ste-
phensi mosquitoes, the main vector of Plasmodium falcipa-
rum malaria in the Indian subcontinent.6 The goal is to re-
place the wild mosquito population with transgenic
mosquitoes that are refractory vectors of human disease. Re-
searchers plan to spread the modified genetic information
using gene drive systems—a mechanism to spread trans-
genes in themosquito population at a faster rate thanwould
be expected of mendelian inheritance. This could consti-
tute a significant risk to biodiversity within national bor-
ders, as well as to neighboring countries.
InNovember2010, theWellcomeTrustannouncedthat the
Malaysiangovernmenthadapproved the releaseofgenetically
modified sterilemaleAaegyptimosquitoes to control dengue,
adisease forwhichdrugsorvaccines arenot available andbed
nets are largely ineffective.7 Oxitec, the British biotechnology
companythatdevelopedthetransgenicmosquitoes,hadalready
conducteda trial in theCaymanIslands in2009/2010.Oxitec’s
“sterile”malemosquitoespassa lethalgenetic element to their
offspring, making themunviable. This self-limited strategy is
regarded as relatively safe as it is a new form of the sterile in-
sect technique, commonlyused inagriculture,with theexcep-
tion that in this technique insects are renderedsterileby radia-
tion instead of genetic manipulation. Yet another approach
uses a strain of the symbiotic bacterium Wolbachia to infect
A aegypti mosquitoes, shortening their life span and interfer-
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ingwiththeirabilitytospreaddengueinfectiontohumans.This
biological control study is scheduled to start in Queensland,
Australia, followed byVietnam, if the trial proves successful.8
The Cartagena Protocol
The Cartagena Protocol on Biosafety to the Convention on
Biological Diversity9 is an international agreement that en-
sures safe handling, transport, and use of living modified
organisms, with potential adverse effects on biological di-
versity and taking into account risks to human health. The
treaty entered into force in 2003, with 168 countries hav-
ing signed. The treaty’s language oversees international trade
of genetically modified agricultural products, rather than
genetically modified insects per se.
Clearly, theuniquebiosafetyconcernswiththereleaseofge-
neticallymodifiedmosquitoesrequirespecificguidelines,which
were provided by the Ad Hoc Technical Expert Group on
Risk Assessment and RiskManagement to the Conference of
theParties inNagoya, Japan, inOctober 2010.10However, the
AdHocTechnicalExpertGroupdidnotaddresssignificanttech-
nical issues, such as organisms containing gene drive systems
tospread thegeneticmodification into thenaturalpopulation.
Furthermore,theCartagenaProtocol’sdefinitionoflivingmodi-
fied organisms does not include mosquitoes carrying a sym-
bioticbacterium,suchasWolbachia,because thisdoesnotcon-
stitute a modification through “modern biotechnology.”
Overall, the Cartagena Protocol is designed to ensure the
safe international exchange of livingmodified organisms as
a commodity, intended to resolve European Union/United
States trade disputes involving agrobiotechnological prod-
ucts. The international community therefore urgently needs
new regulatory pathways for research and deployment of
genetically modified arthropods to control disease. The jus-
tification for a new treaty is clear—no state, acting by it-
self, can regulate the transboundary movement of geneti-
cally modified mosquitoes once they are released into the
natural environment.
Toward a Global Treaty on Genetic or Biological
Modifications of Arthropod Vectors
Anew treaty should establish an international process for rig-
orous examination of scientific evidence, ethical values, and
dispassionate review before genetically or biologically modi-
fiedarthropodvectorsarereleasedintothenaturalenvironment.
Scientific Evidence and the Precautionary Principle.
The treaty bodywould have to rigorously examine the avail-
able scientific evidence and consider the benefits and risks
of the alternative models to introduce genetic or biological
modifications of mosquitoes, given their differential eco-
logical effects. If the scientific evidence demonstrates sig-
nificant disease reductionwith low ecological risks, the pre-
cautionary principle should not impedemeaningful benefits
for human health. Conversely, if the treaty body finds the
human value is unestablished or the ecological risks are high,
it should exercise caution.
The Relative Value of Health and the Environment. The
international resolution of complex social problems does not
lie solely in scientific assessment, but also entails values.
Clearly, both human health and ecological concerns are im-
portant and interrelated. The treaty body should give great
weight to the ability of science to ameliorate serious risks
to human health. A long-term perspective is also impor-
tant because ecological deterioration not only harms the en-
vironment, but can also present future risks to humanhealth.
The Least Harmful Alternative. The treaty body should
choose the genetic or biological innovations with the lowest
ecological risks.Forexample,Wolbachia symbiontshavebeen
extensively used in fruit fly control, so might be regarded as
a lower riskmethodcomparedwithgeneticallymodifiedmos-
quitoescarryinggenedrivesystemsintendedtopropagate“new”
genetic information in the wild mosquito population. Over-
all, genetically or biologicallymodified arthropods shouldbe
released into the environment only as a last resort.
Independent Deliberation in Advance of Release. Im-
portantly, genetically or biologically modified arthropods
should be released into the environment only after a full and
independent scientific andethical evaluation.Thecurrentprac-
tice whereby private companies, researchers, or states make
unilateral decisions without transparency and accountability
is unacceptable. The benefits and harms of release will ac-
crue not only to those actors, but also to entire regions of the
world. Consequently, fair and dispassionate decision mak-
ing processes, with broad international agreement, are vital.
Ultimately, the international community needs a legal
framework that harmonizes environmental safety with the
humanitarian responsibility to assist nations under the so-
cial and economic burdens of disease.
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